凝血酶調(diào)節(jié)素加強人類循環(huán)前驅(qū)細(xì)胞于缺血肢之療效ppt課件_第1頁
凝血酶調(diào)節(jié)素加強人類循環(huán)前驅(qū)細(xì)胞于缺血肢之療效ppt課件_第2頁
凝血酶調(diào)節(jié)素加強人類循環(huán)前驅(qū)細(xì)胞于缺血肢之療效ppt課件_第3頁
凝血酶調(diào)節(jié)素加強人類循環(huán)前驅(qū)細(xì)胞于缺血肢之療效ppt課件_第4頁
凝血酶調(diào)節(jié)素加強人類循環(huán)前驅(qū)細(xì)胞于缺血肢之療效ppt課件_第5頁
已閱讀5頁,還剩19頁未讀 繼續(xù)免費閱讀

下載本文檔

版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進(jìn)行舉報或認(rèn)領(lǐng)

文檔簡介

1、 Thrombomodulin Enhances the Therapeutic Effects of Human Circulating Progenitor Cells in Ischemic Limb葉葉 宏宏 一一Hung-I Yeh MD., PhD. Hung-I Yeh MD., PhD. Vice Director, Dept. Vice Director, Dept. Internal Medicine, Internal Medicine, Mackay Memorial Mackay Memorial HospitalHospitalProfessor, Taipei P

2、rofessor, Taipei Medical UniversityMedical UniversityIntroduction The risk of peripheral arterial disease (PAD) of the lower extremities increases 2- to 3-fold for every 10 years increase in age after the age of 40 years Patients with critical leg ischemia require restoration of blood flow to heal w

3、ounds, relieve ischemic pain, and prevent limb loss Stem cell therapy for critical leg ischemia has been shown promising Overview of clinical studies evaluating different cell types Reference NCell typeMean cell no. appliedOutcomeDurdu et al. (2006)Gu et al.2006Higashi et al.2004Inaba S et al.2002Is

4、hida et al.2005Lenk et al.2004Miyamoto et al.2004Saigawa T et al.2004Tateishi-Yujama et al. 2002282835776712847BMMNCsBMMNCs+ G-CSF BMMNCsPBMNCs+ G-CSF PBMNCs+ G-CSF CPCBMMNCsBMMNCsBMMNCsNot reportedNot reported0.3-1.6x1091.37-14.9x1070.75-1,0 ml39 24x106Not reported6.04 1.58x107/kgA: 0.7-2.7 x109B:

5、0.88-2.8 x109ABI, peak walking time, collateral vessel formation ABI, TcO2 pain-free walking time, ulcer healing amputation rateABI, TcO2 pain-free walking time, leg blood flow response to acetylcholine Pain relief maximum walking distanceABI, TcO2 pain-free walking time, ulcer healing ABI, TcO2 pai

6、n-free walking distance, flow-dependent vasodilatationABI,pain-free walking time, perfusion blood flow, rest pain ABI, TcO2 ,relief of rest pain, ulcer healing number of small blood vesselsABI, TcO2 , rest pain , pain-free walking time, number of collateral vesselsN. Lachmann and S. Nikol VASA 2007c

7、entrifugationbuffy coatdensity gradient centrifugationmononuclear cell fraction cultured in EGM2100 mmDay 7Circulating Progenitor Cells50 mmPoached egg-like cellCobble stone-like cellFiber-like cellDay 21Day 21Day 14Colony forming unitTwo different types of cultured MNCEarlyLatespindlecobblestoneSha

8、pe7 days2-3 weeksPeak growth lesslesslessmoremoremoremorelessSurface marker VE-cadherin Flt-1 KDR CD45Angiogenic cytokines VEGF IL-8 moremorelesslesslessmoreNO production unableableCapillary tube formation Modified from Yoon et al. Circulation 2005 and Hur J et al. ATVB 2004heterogeneoushomogeneousP

9、opulations goodgoodAngiogenic potential How to enhance the therapeutic potential of EPC in ischemic disease? Thrombomodulin (TM) Recombinant TMD1, TMD2, TMD23 and TMD123 were prepared by Prof. Wu HL (NCKU). TM fragments, esp TMD23 induces cell proliferation and migration, and promote angiogenesis, s

10、uggesting that TM fragments may play a role in the formation of new vessels. (Circ 2005).Hypothesis: TM auguments angiogenic potential of EPCExtracellularIntracellularCOOHD IPlasma membraneEGF domainLectin-like domainO-glycosylationdomainTransmembranedomainD IID IIID IVD VcytoplasmicdomainTM express

11、ion in human PBMNC cultured in different mediumEndoCult EGM2 PBMCHAECDay 7Day 7Day 21Day 2150 mm802040600100TM Conc. (pg/mL)Day 7Day 14Day 21Medium onlyAll p0.05TM is released by cultured human PBMNCCFU in PBMNC respectively treated with TMD1, TMD23 and TMD123 (100 ng/ml)CFU number/ 1x106 PBMC P 0.0

12、5CtrlTMD1 TMD23 TMD123Chemotaxic effects of TMD (100 ng/ml) on human early EPC300 mmCtrlTMD123TMD23TMD1All P 0.05Migrated cells/ fieldCtrlTMD1 TMD23 TMD123mRNA expression of early EPC treated with TMD23 (100 ng/ml) for 72h 012345Introduction FoldCtrlTMD23PAI-1Ang-1 Ang-2eNOSIL-8VEGF* P 0.05Gelatin z

13、ymography of early EPC medium treated with TMD23 (100 ng/ml) for 72 hourCtrl TMD 23 Ctrl TMD 23Medium HAEC PMA24 h72hMMP9MMP2MMP2MMP9Percentage (%)Ctrl 24hTMD23 24hCtrl 72hTMD23 72hMediumGelatin zymography of early EPC treated with TMD23 (100 ng/ml) for 72 hourMMP9MMP2Ctrl TMD23* P0.05P=0.06Percenta

14、ge (%)MMP2MMP9CtrlTMD23Western blotting of early EPC treated with TMD23 (100 ng/ml)ErkP38PErkPP38(Min) 0 10 30 120AktPAktGAPDH 0 10 30 120GroupOsmotic pumpArtery ligationInjected cells1PBS+Saline2PBS+Early EPC3TMD23+Saline4TMD23+Early EPCPump: 85.4 ng /g /day TMD23 protein Female athymic mice were i

15、mplanted osmotic pump into peritoneumhindlimb artery ligation1 day1 daySacrifice Detect blood flow in hindlimb by Laser Doppler scan before Injected cells and day 7 and 21 after injection21 daysEvaluation of TM, cell therapy, or both in murine hindlimb ischemia model Effects of combined TMD23 and ea

16、rly EPCs in murine hindlimb ischemia model20406080100SalineSalineEarly EPCEarly EPCTMD23PBS8888Pump:%n=AmputationToe necrosisLimb salvagePBS/salinePBS/early EPCTM/salineTM/early EPC 0.20.40.81.00.6Perfusion Ratio01.27210(days)0 days7 days21 daysAnalysis of Perfusion in Ischemic LimbsAll p0.05*TM + e

17、arly EPCM-PECAM-1 / LamininPBS/SalineTMD23/SalineTMD23/eEPCPBS/eEPCCapillary density in calf of hindlimb ischemic mice treated with early EPC + TMD23 p0.05 compared with PBS# p0.05 compared with TM/ eEPC*Capillary / myocyte densitySalinePBSTMD23Pump:0.51.01.52.0*#*SalineEarly EPCEarly EPC50 mmhNAThi

18、gh tissue of hindlimb ischemic mice treated with early EPC + TMD23 (21st days)H33258/hNAH33258hNA/h-CD31 hNA/vWF20406080100Normal calfSalineSalineEarly EPCEarly EPCPBSTMD23Muscle weigh ( mg )*Pump:# p0.05 compared with normal calf* p0.05 compared with PBSCalf muscle in hindlimb ischemic mice treated with TMD23 and early EPCSummary Human early EPC express and release TM, the amount of which increased along the initial 21 days of culture TMD23 increases CFU of cultured PBMNC TMD23 and TMD123 fr

溫馨提示

  • 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。

評論

0/150

提交評論